Market dialogue LIMS molecular pathology

In the spring of 2025, the Capital Region of Denmark and Region Zealand conducted a preliminary market assessment regarding LIMS for pathology with selected LIMS vendors, as preparation for a more targeted market dialogue. The initial market assessment revealed that some aspects remain unclear for the regions regarding what the market is able to offer. This is especially the case for molecular pathology, where further insight is needed into which standard systems, currently available on the market, can meet the identified needs and how they do so—particularly how they support seamless digital integration with the pathology unit’s “classical pathology” workflow. The regions thus wish to gain greater insight into what the market can deliver and are therefore initiating the present market dialogue, consisting of two separate sessions: one targeting the pathology unit’s “classical pathology” and one targeting the pathology unit’s “molecular pathology”. There will be overlapping requirements between the two. It is important to note that the regions have not yet decided whether the future procurement will involve one or two integrated LIMS solutions. The market dialogue is intended to help clarify this. This market dialogue regards LIMS Molecular Pathology and there will be conducted another market dialogue regarding LIMS Pathology in parrallel with a separate invitation. Please read the detailed invitation in the message module in EU Supply